Appendix.

The Society of Gynecologic Oncology’s (SGO’s) Clinical Practice Committee has developed a series of Clinical Documents designed to improve the overall quality of women’s cancer care; reduce the use of unnecessary, ineffective or harmful interventions; as well as facilitate the optimal treatment of patients with a goal to maximize the therapeutic benefit, and minimize the risk of harm, at acceptable cost.

Clinical Documents are intended to be educational devices that provide information that may assist healthcare providers in caring for patients. This Clinical Document is not a rule and should not be construed as establishing a legal standard of care or as encouraging, advocating, requiring or discouraging any particular treatment. Clinical Documents are not intended to supplant the judgment of the health care provider with respect to particular patients or special clinical situations. Clinical decisions in any particular case involve a complex analysis of a patient’s condition and available courses of action with the ultimate determination to be made by the health care provider in light of each individual patient’s circumstances. Therefore, clinical considerations may lead a healthcare provider to appropriately take a course of action that varies from this Document.

This Clinical Document has met SGO’s criteria of an Evidence Based Clinical Document.

In developing clinical documents, SGO follows a rigorous process to assure that any conflicts of interest are disclosed and appropriately addressed and that relationships with manufacturers and other third parties do not influence the development process.


The authors provided this information as a supplement to their article.
More specifically, SGO adheres to the principles adopted by the Council of Medical Specialty Societies (“CMSS”) in developing, adopting and promulgating clinical guidelines and consensus statements. Consistent with CMSS principles, SGO received no funding from any manufacturer to support the development of this Clinical Document nor any other clinical consensus statement or practice guideline developed and published by SGO.

In accordance with CMSS principles, SGO requires that its clinical documents be subject to multiple levels of review beginning with a review by SGO’s full Clinical Practice Committee. After review and approval by the Clinical Practice Committee, Clinical Documents are submitted to the SGO Council which is SGO’s governing body which reviewed and approved the Clinical Document for submission to SGO’s Journal.

In accordance with those principles, each member of the task force, which developed the Clinical Document, executed a detailed disclosure statement. None of the members of the task force has a financial relationship or other relationship that are of conflict in the writing of this document.


The authors provided this information as a supplement to their article.